(3) Amount of Separate Payment for Diagnostic Radiopharmaceuticals Exceeding the Threshold As discussed in the CY 2025 OPPS/ASC final rule with comment period (89 FR 93955 through 93959), once we determine that the per day cost of a nonpass-through diagnostic radiopharmaceutical exceeds the cost threshold, proposed to be $655 per day for CY 2026, we will then assign that radiopharmaceutical to an APC, making it a specified covered outpatient drug (SCOD) per section 1833(t)(14)(B) of the Act
We observed that the expression of AQP4 significantly declined with GHK treatment
However, their effects are often transient
They reduce overall immune activity, which decreases autoimmune attacks but also weakens defense against infections, reduces cancer surveillance, and impairs wound healing
A thorough literature search was conducted using published scientific papers from databases such as ACS Publications Today, Frontiers, ScienceDirect, Scopus, Google Scholar, and Wiley Online Library